Testicular Lymphoma Regimen
| Treatment Component | Details | Side Effects and Incidence |
| R-CHOP Chemotherapy | – Rituximab: 375 mg/m² IV on day 1 | – Neutropenia: 28% |
| – Cyclophosphamide: 750 mg/m² IV on day 1 | – Infections: 4% | |
| – Doxorubicin: 50 mg/m² IV on day 1 | – Neurologic Toxicity: 13% | |
| – Vincristine: 1.4 mg/m² (max 2 mg) IV on day 1 | – Fever, Muscle Aches, Headache, Shivers: Common due to low white blood cell counts | |
| – Prednisone: 100 mg orally on days 1–5 | – Nausea and Vomiting: Common | |
| – Administered every 21 days for 6–8 cycles | – Hair Loss: Common | |
| – Heart Problems: Possible due to cyclophosphamide and doxorubicin | ||
| Radiation Treatment | – Contralateral Testis Irradiation: 30 Gy | – Fatigue and Skin Changes: Common but not detailed in the study |
| – Administered after completion of chemotherapy | ||
| Intrathecal CNS Prophylaxis | – Intrathecal Methotrexate (IT-MTX): 12 mg per dose | – Headache, Nausea, Vomiting, Back Pain, Fever: Occurred after 30.7% of doses |
| – Administered during the first two courses of R-CHOP | – Significant Neurologic Events (Paresthesias or Paralysis): 3.1% of doses |
All patients were planned to receive CNS prophylaxis with IT-MTX, 12 mg total dose, weekly for four times, during the first two R-CHOP21 courses.
All patients were restaged after three courses of R-CHOP21. Stage I patients received six courses of R-CHOP21.
Stage II patients received a total of six or eight courses of R-CHOP21 if they had a complete response (CR) or partial response (PR) after the third course. Chemoimmunotherapy was delivered in an outpatient setting.
References:
https://ascopubs.org/doi/10.1200/JCO.2010.31.4187
Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187. Epub 2011 Jun 6. PMID: 21646602.